trial

Glycine vs Placebo for the Schizophrenia Prodrome

NCTId NCT00291226
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 8 (actual)
Sponsored by Yale University
Primary completion 2009-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
8 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-03
Primary completion
2009-07
Eligibility
ALL · 13 Years · 35 Years

Interventions & indications

Drugs
glycine

Sponsors

Yale UniversityLead Sponsor
Glytech, IncCollaborator
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
Scott W. Woods, MDPrincipal Investigator

Sites

1 total
New Haven, United States

Linked catalysts

1
Glycine vs Placebo for the Schizophrenia Prodrome — primary completion2009-07

Facts & assertions

4 sourced
Enrollment
8
Phase
PHASE2,PHASE3
Primary Completion Date
2009-07
Status
COMPLETED
relationships
The graph out of here
drug
glycine
drug
lead_sponsor
Yale University
company
collaborator
Glytech, Inc
company
National Alliance for Research on Schizophrenia and Depression
company
indication
Schizophrenia Prodrome
indication
investigator
Scott W. Woods, MD
person